Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Evaxion Biotech A/S ADR (EVAX)

Evaxion Biotech A/S ADR (EVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Wall Street - shutterstock_1321462400
Stock Index Futures Mixed on Pressure from Rising Bond Yields, Oil Prices Rise After Saudi Output Cuts Barchart - Mon Jun 5, 2023

June S&P 500 futures (ESM23) are up +0.01%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.25% this morning as market participants digested the U.S. debt ceiling agreement, while U.S. Treasury...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
LULU : 298.14 (-0.73%)
MMM : 101.32 (-0.30%)
AMZN : 200.00 (+1.22%)
VOLCB.S.DX : 31.615 (-1.77%)
MRO : 28.18 (-2.05%)
DVN : 47.03 (-2.24%)
OXY : 61.79 (-0.85%)
DBRG : 13.16 (-1.57%)
RAIN : 1.2100 (-1.63%)
EVAX : 3.21 (+1.90%)
Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update Globe Newswire - Wed Aug 10, 2022

Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLCAnnounced successful production of personalized cancer immunotherapies for...

EVAX : 3.21 (+1.90%)
Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10 Globe Newswire - Fri Jul 29, 2022

COPENHAGEN, Denmark, July 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 3.21 (+1.90%)
Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target Globe Newswire - Thu Jun 30, 2022

COPENHAGEN, Denmark, June 30, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 3.21 (+1.90%)
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer Globe Newswire - Thu Jun 23, 2022

COPENHAGEN, Denmark, June 23, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 3.21 (+1.90%)
Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital Globe Newswire - Tue Jun 7, 2022

COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 3.21 (+1.90%)
Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update Globe Newswire - Wed May 11, 2022

Received regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanomaCompleted recruitment for Phase 1/2a...

EVAX : 3.21 (+1.90%)
Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11 Globe Newswire - Fri Apr 29, 2022

COPENHAGEN, Denmark, April 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 3.21 (+1.90%)
Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma Business Wire - Tue Apr 26, 2022

Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of...

EVAX : 3.21 (+1.90%)
PSNL : 1.5300 (+28.57%)
Evaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personalized Cancer Immunotherapies Globe Newswire - Wed Apr 6, 2022

Tuesday, April 12th @ 12:30 pm ET COPENHAGEN, Denmark, April 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the...

EVAX : 3.21 (+1.90%)

Barchart Exclusives

How to Avoid Being Influenced By Social Media On Investment Decisions Barchart - Sun Jul 7, 2:56PM CDT
Social media's influence on investment decisions can lead to impulsive and costly mistakes. Explore the impact of social media on finance and provides strategies for making informed, independent investment choices. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot